Modeling the human bladder tissue using three dimensional in vitro approaches as a tool for drug screening platforms
Source abstract
Abstract
The main function of bladder tissue is urine accumulation and excretion, and it is composed of five layers (mucus layer, epithelial layer, lamina propria, muscular layer, and perivesical tissue). Distinct conditions can compromise morphology and function of the bladder tissue, including congenital disorders, trauma, inflammation and/or cancer. Bladder cancer (BC) is one of the most common genitourinary tract complications, being classified as non-muscle invasive BC (NMIBC) or muscle-invasive BC (MIBC). NMIBC usually affects the mucosa and submucosa of the bladder tissue, requiring tumor resection, followed by intravesical administration of mitomycin-C. MIBC commonly affects the deeper layers of bladder, being associated with the origin of metastases, and it is recommended to perform a radical cystectomy followed by cisplatin-based neoadjuvant chemotherapy. In vitro techniques have been explored as drug screening platforms to test new therapeutic regimens, specifically 3D models that are gaining more attention with a wide range of applications. These 3D structures suitably recreate morphology, complexity and function of bladder tissue or tumor microenvironment (cell-cell and cell-extracellular matrix interactions). Additionally, 3D models represent a useful tool prior to in vivo assays. Different platforms can be developed for closer resembling in vivo urothelial epithelium and bladder tumor, and therefore, for studying tissue and/or tumor morphology, drugs permeability, among others. Following these purposes, 3D bladder models are already being designed, namely spheroids, multilayer models, organ-on-chip, bioprinting, and organoids. Hence, this review aims to highlight and summarize the current advances in the development of 3D in vitro bladder models. STATEMENT OF SIGNIFICANCE: Bladder cancer is classified as NMIBC or MIBC by tissue layer involvement. NMIBC and MIBC are treated with surgery and chemotherapy accordingly. 3D in vitro models accurately mimic bladder tissue and tumor environment. Organoids, spheroids, and hydrogels are established drug screening tools. 3D models show strong potential for translation into clinical applications.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: 3D Printing in Biomedical Research · Tissue Engineering and Regenerative Medicine · Additive Manufacturing and 3D Printing Technologies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Collagen - emerging collagen based therapies hit the patient10.1016/j.addr.2012.08.010 ↗
2. Tissue engineering of urinary bladder and urethra: advances from bench to patients10.1155/2013/154564 ↗
3. Regenerative medicine of the bladder
4. Modeling human bladder cancer10.1007/s00345-018-2369-5 ↗
5. Diagnosis and staging of bladder cancer10.1016/j.hoc.2021.02.004 ↗
6. Bladder cancer: a review10.1001/jama.2020.17598 ↗
7. Modeling physiological events in 2D vs. 3D cell culture10.1152/physiol.00036.2016 ↗
8. 2D and 3D cell cultures - a comparison of different types of cancer cell cultures
9. Is it time to start transitioning from 2D to 3D cell culture?10.3389/fmolb.2020.00033 ↗
10. Recreating the extracellular matrix: novel 3D cell culture platforms in cancer research10.1111/febs.16778 ↗
11. The role of the mucosa in normal and abnormal bladder function10.1111/bcpt.12626 ↗
12. Innovative applications of natural polysaccharide polymers in intravesical therapy of bladder diseases10.1016/j.carbpol.2025.123307 ↗
13. Glycosaminoglycan therapy for bladder diseases: emerging new treatments10.1016/j.eursup.2011.06.001 ↗
14. Urothelial progenitors in development and repair10.1007/s00467-021-05239-w ↗
15. The urothelium: a multi-faceted barrier against a harsh environment10.1038/s41385-022-00565-0 ↗
16. Cell biology and physiology of the uroepithelium10.1152/ajprenal.00327.2009 ↗
17. The urothelium: life in a liquid environment10.1152/physrev.00041.2019 ↗
18. The uroepithelium: not just a passive barrier10.1046/j.1600-0854.2003.00156.x ↗
19. Urothelial injuries and the early wound healing response: tight junctions and urothelial cytodifferentiation10.1007/s00418-005-0770-9 ↗
20. Rapid differentiation of superficial urothelial cells after chitosan-induced desquamation10.1007/s00418-008-0492-x ↗
21. Lamina propria: the functional center of the bladder?10.1002/nau.22465 ↗
22. The role of the human bladder lamina propria myofibroblast10.1046/j.1464-410X.2003.03802.x ↗
23. Spontaneous activity and the urinary bladder
24. Urinary bladder contraction and relaxation: physiology and pathophysiology10.1152/physrev.00038.2003 ↗
25. Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma10.1038/ncb2956 ↗
26. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
27. Epidemiology of bladder cancer10.1016/j.hoc.2014.10.001 ↗
28. Approaches to non-muscle-invasive bladder cancer10.1007/s11912-021-01091-1 ↗
29. Bladder cancer: epidemiology, staging and grading, and diagnosis10.1016/j.urology.2005.07.062 ↗
30. Identification of genetic risk factors for familial urinary bladder cancer: an exome sequencing study10.1200/PO.21.00115 ↗
31. Bladder cancer10.1016/S0140-6736(16)30512-8 ↗
32. Bladder cancer: current challenges and future directions10.3390/medicina57080749 ↗
33. Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer10.1007/s00262-023-03376-9 ↗
34. Epidemiology, screening, and prevention of bladder cancer10.1016/j.euo.2022.10.003 ↗
35. Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer10.1038/nrurol.2014.52 ↗
36. Landmarks in non-muscle-invasive bladder cancer10.1038/nrurol.2014.130 ↗
37. Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia: the PEONY phase 3 randomized clinical trial10.1001/jamaoncol.2019.3692 ↗
38. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial10.1001/jamaoncol.2019.0270 ↗
39. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial10.1016/S0140-6736(23)00221-0 ↗
40. Perioperative immunotherapy in muscle-invasive bladder cancer10.1007/s11864-023-01113-z ↗
41. Current and future landscape of perioperative treatment for muscle-invasive bladder cancer10.3390/cancers15030566 ↗
42. Treatment of muscle-invasive and advanced bladder cancer in 2020
43. Diagnosis and treatment of bladder cancer
44. Systemtherapie des harnblasenkarzinoms10.1007/s00120-020-01420-5 ↗
45. Nanotechnology in bladder cancer: current state of development and clinical practice10.2217/nnm.14.212 ↗
46. Nanotechnology in bladder cancer: diagnosis and treatment10.3390/cancers13092214 ↗
47. Current advances in the application of nanomedicine in bladder cancer10.1016/j.biopha.2022.114062 ↗
48. Recent advances on cell culture platforms for in vitro drug screening and cell therapies: from conventional to microfluidic strategies10.1002/adhm.202202936 ↗
49. The third dimension bridges the gap between cell culture and live tissue10.1038/nrm2236 ↗
50. Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy10.1016/j.jconrel.2012.04.045 ↗
51. Drug delivery to solid tumors: the predictive value of the multicellular tumor spheroid model for nanomedicine screening10.2147/IJN.S146927 ↗
52. Bladder cancer: therapeutic challenges and role of 3D cell culture systems in the screening of novel cancer therapeutics10.1186/s12935-023-03069-4 ↗
53. Could 3D models of cancer enhance drug screening?10.1016/j.biomaterials.2019.119744 ↗
54. Preclinical testing techniques: paving the way for new oncology screening approaches10.3390/cancers15184466 ↗
55. A brief history of cell culture: from Harrison to organs-on-a-chip10.3390/cells13242068 ↗
56. Spheroids as a type of three-dimensional cell cultures - examples of methods of preparation and the most important application10.3390/ijms21176225 ↗
57. Immortalized human urothelial cells as a model of arsenic-induced bladder cancer10.1016/j.tox.2008.03.020 ↗
58. Immortalisation of normal human urothelial cells compromises differentiation capacity10.1016/j.eururo.2011.02.022 ↗
59. Analyses in human urothelial cells identify methylation of miR-152, miR-200b and miR-10a genes as candidate bladder cancer biomarkers10.1016/j.bbrc.2013.07.021 ↗
60. Bladder organoids and spheroids: potential tools for normal and diseased tissue modelling10.21873/anticanres.13219 ↗
61. 3D cell culture systems: tumor application, advantages, and disadvantages10.3390/ijms222212200 ↗
62. Life is 3D: boosting spheroid function for tissue engineering10.1016/j.tibtech.2016.08.004 ↗
63. The liquid overlay technique is the key to formation of co-culture spheroids consisting of primary osteoblasts, fibroblasts and endothelial cells10.3109/14653249.2011.583233 ↗
64. Mesenchymal stem cell spheroids retain osteogenic phenotype through alpha2beta1 signaling10.5966/sctm.2015-0412 ↗
65. Scaffold-based 3D cell culture models in cancer research10.1186/s12929-024-00994-y ↗
66. Three-dimensional cell cultures in drug discovery and development10.1177/1087057117696795 ↗
67. Urine-derived bladder cancer organoids (urinoids) as a tool for cancer longitudinal response monitoring and therapy adaptation10.1038/s41416-023-02494-6 ↗
68. Patient-derived bladder cancer organoid model to predict sensitivity and feasibility of tailored precision therapy10.1097/CU9.0000000000000219 ↗
69. Organoids10.1038/s43586-022-00174-y ↗
70. Organoids: the current status and biomedical applications10.1002/mco2.274 ↗
71. Tumor evolution and drug response in patient-derived organoid models of bladder cancer10.1016/j.cell.2018.03.017 ↗
72. Research progress, challenges, and breakthroughs of organoids as disease models10.3389/fcell.2021.740574 ↗
73. Organoids: a systematic review of ethical issues10.1186/s13287-022-02950-9 ↗
74. Organ-on-a-chip: a survey of technical results and problems10.3389/fbioe.2022.840674 ↗
75. A comprehensive review of organ-on-a-chip technology and its applications10.3390/bios14050225 ↗
76. Organ-on-a-chip devices: technology progress and challenges
77. Organ-on-chip technology: opportunities and challenges10.1016/j.biotno.2024.01.001 ↗
78. 3D bioprinting of biomaterials: a review of advances in techniques, materials, and applications10.1002/pat.70324 ↗
79. A review on cell damage, viability, and functionality during 3D bioprinting
80. Organoid and spheroid tumor models: techniques and applications10.3390/cancers13040874 ↗
81. Multicellular spheroid: 3-D tissue culture model for cancer research
82. Characterization of the physical properties of tumor-derived spheroids reveals critical insights for pre-clinical studies10.1038/s41598-019-43090-0 ↗
83. 3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained10.1038/srep19103 ↗
84. Impact of spheroid culture on molecular and functional characteristics of bladder cancer cell lines
85. Multidrug resistance in a urothelial cancer cell line after 3, 1-hour exposures to mitomycin C10.1016/j.juro.2007.06.047 ↗
86. Multicellular tumor spheroids (MCTS) as a 3D in vitro evaluation tool of nanoparticles10.1002/smll.201702858 ↗
87. Assessing the cytotoxic potential of glycoalkaloidic extract in nanoparticles against bladder cancer cells10.1111/jphp.13145 ↗
88. Comparative analysis of 3D bladder tumor spheroids obtained by forced floating and hanging drop methods for drug screening10.3389/fphys.2017.00605 ↗
89. Targeting 3D bladder cancer spheroids with urease-powered nanomotors10.1021/acsnano.8b06610 ↗
90. Cytotoxic and chemosensitizing effects of glycoalkaloidic extract on 2D and 3D models using RT4 and patient derived xenografts bladder cancer cells10.1016/j.msec.2020.111460 ↗
91. Enhancing the photodynamic effect of hypericin in human bladder transitional cell carcinoma spheroids by the use of the oxygen carrier, perfluorodecalin
92. Mechanisms of the antineoplastic effects of new fluoroquinolones in 2D and 3D human breast and bladder cancer cell lines10.3390/cancers16122227 ↗
93. Profiling and targeting of energy and redox metabolism in grade 2 bladder cancer cells with different invasiveness properties10.3390/cells9122669 ↗
94. Effect of four fluoroquinolones on the viability of bladder cancer cells in 2D and 3D cultures10.3389/fonc.2023.1222411 ↗
95. Selective cytotoxicity of gemcitabine in bladder cancer cell lines10.1097/00001813-200207000-00002 ↗
96. Selective reovirus killing of bladder cancer in a co-culture spheroid model10.1016/S0168-1702(03)00045-5 ↗
97. Tissue-engineered human 3D model of bladder cancer for invasion study and drug discovery10.1016/j.biomaterials.2017.08.041 ↗
98. Quantitative image analysis of intracellular protein translocation in 3-dimensional tissues for pharmacodynamic studies of immunogenic cell death10.1016/j.jconrel.2023.11.023 ↗
99. A simple three-dimensional in vitro culture mimicking the in vivo-like cell behavior of bladder patient-derived xenograft models10.3390/cancers12051304 ↗
100. Spheroid-based drug screen: considerations and practical approach10.1038/nprot.2008.226 ↗